If the plaintiffs have their way, a federal judge should not dismiss their complaint that Forest Laboratories Inc. misrepresented the safety of using antidepressants Celexa and Lexapro in a pediatric population.
In a lawsuit in Massachusetts federal court, the plaintiffs assert that the defendants suppressed negative study results, made false representations in advertising and marketing materials, selectively disseminated medical publications in order to mislead physicians and patients, and induced prescribers by giving physicians research grants, honoraria, gifts and paying them for promotional speeches.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
